Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani, Rayne H. Rouce, Enli Liu, et al.
Molecular Therapy (2017) Vol. 25, Iss. 8, pp. 1769-1781
Open Access | Times Cited: 390

Showing 1-25 of 390 citing articles:

The Tumor Microenvironment Innately Modulates Cancer Progression
Dominique C. Hinshaw, Lalita A. Shevde
Cancer Research (2019) Vol. 79, Iss. 18, pp. 4557-4566
Open Access | Times Cited: 2522
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu, David Marín, Pinaki P. Banerjee, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 6, pp. 545-553
Open Access | Times Cited: 1625
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi, Antoni Ribas
Nature reviews. Immunology (2019) Vol. 20, Iss. 1, pp. 25-39
Open Access | Times Cited: 1170
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Alex M. Abel, Chao Yang, Monica S. Thakar, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 933
NK cell-based cancer immunotherapy: from basic biology to clinical development
Sizhe Liu, Vasiliy Galat, Yekaterina Galat, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 488
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
Peter Bannas, Julia Hambach, Friedrich Koch‐Nolte
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 467
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
Tobias Bald, Matthew F. Krummel, Mark J. Smyth, et al.
Nature Immunology (2020) Vol. 21, Iss. 8, pp. 835-847
Open Access | Times Cited: 369
NK Cell-Based Immune Checkpoint Inhibition
Muhammad Khan, Sumbal Arooj, Hua Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 276
Role of immune cells in the removal of deleterious senescent cells
Abhijit Kale, Amit Sharma, Alexandra Stolzing, et al.
Immunity & Ageing (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 258
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
Lin Xiao, Dongzhi Cen, Haining Gan, et al.
Molecular Therapy (2019) Vol. 27, Iss. 6, pp. 1114-1125
Open Access | Times Cited: 226
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Kris M. Mahadeo, Sajad Khazal, Hisham Abdel‐Azim, et al.
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 1, pp. 45-63
Open Access | Times Cited: 208
CAR-NK for tumor immunotherapy: Clinical transformation and future prospects
Wenxiu Wang, Jingting Jiang, Changping Wu
Cancer Letters (2019) Vol. 472, pp. 175-180
Open Access | Times Cited: 190
Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
May Daher, Katayoun Rezvani
Current Opinion in Immunology (2018) Vol. 51, pp. 146-153
Open Access | Times Cited: 188
Cell membrane-coated nanosized active targeted drug delivery systems homing to tumor cells: A review
Zehui He, Yongtai Zhang, Nianping Feng
Materials Science and Engineering C (2019) Vol. 106, pp. 110298-110298
Closed Access | Times Cited: 176
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
Amaia Eleonora Maennling, Mehmet Kemal Tur, Marcus Niebert, et al.
Cancers (2019) Vol. 11, Iss. 12, pp. 1826-1826
Open Access | Times Cited: 173
BCMA-targeted immunotherapy for multiple myeloma
Bo Yu, Tianbo Jiang, Delong Liu
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 160
CAR-macrophage: A new immunotherapy candidate against solid tumors
Yizhao Chen, Zhiying Yu, Xuewen Tan, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 139, pp. 111605-111605
Open Access | Times Cited: 160
Human immunology and immunotherapy: main achievements and challenges
Jezabel Varadé, Susana Magadán, África González‐Fernández
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 4, pp. 805-828
Open Access | Times Cited: 155
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
Christopher Sloas, Saar Gill, Michael Klichinsky
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 151
Advances in Universal CAR-T Cell Therapy
Haolong Lin, Jiali Cheng, Wei Mu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 137
CAR-NK cells for cancer immunotherapy: from bench to bedside
Leisheng Zhang, Meng Yuan, Xiaoming Feng, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 128
Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
Amani Makkouk, Xue Yang, Taylor Barca, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 12, pp. e003441-e003441
Open Access | Times Cited: 127
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors
Apostolia M. Tsimberidou, Karlyle Van Morris, Henry Hiep Vo, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 117
Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle
Qianqian Li, Zhaoqing Shi, Fan Zhang, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 1, pp. 107-134
Open Access | Times Cited: 109
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Lucila Nassif Kerbauy, Nancy D. Marín, Mecit Kaplan, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 13, pp. 3744-3756
Open Access | Times Cited: 108
Page 1 - Next Page

Scroll to top